Modulators of calpain activity: inhibitors and activators as potential drugs

References

• Guroff G. A neutral, Calcium-activated proteinase from the soluble fraction of rat brain. J Biol Chem. 1964;239:149–155.
   PubMed Web of Science ®Google Scholar
• Cong J, Goll DE, Peterson AM, et al. The role of autolysis in activity of the Ca2+-dependent proteinases (mu-calpain and m-calpain). J Biol Chem. 1989;264:10096–10103.
   PubMed Web of Science ®Google Scholar
• YoshimuraS N, Kikuchi T, Sasakis T, et al. Two distinct Ca2+ proteases (calpain I and calpain II) purified concurrently by the same method from rat kidney. J Biol Chem. 1983;258:8883–8889.
   PubMed Web of Science ®Google Scholar
• Goll DE, Thompson VF, Li H, et al. The calpain system. Physiol Rev. 2003;83:731–801.
   PubMed Web of Science ®Google Scholar
• Inomata M, Nomoto M, Hayashi M, et al. Comparison of low and high calcium requiring forms of the calcium-activated neutral protease (CANP) from rabbit skeletal muscle. J Biochem. 1984;95:1661–1670.
   PubMed Web of Science ®Google Scholar
• Sorimachi H, Hata S, Ono Y. Expanding members and roles of the calpain superfamily and their genetically modified animals. Exp Anim. 2010;59:549–566.
   PubMed Web of Science ®Google Scholar
• Sorimachi H, Hata S, Ono Y. Calpain chronicle–an enzyme family under multidisciplinary characterization. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:287–327.
   PubMed Web of Science ®Google Scholar
• Hosfield C, Elce J, Davies P, et al. Crystal structure of calpain reveals the structural basis for Ca(2+)-dependent protease activity and a novel mode of enzyme activation. Embo J. 1999;18:6880–6889.
   PubMed Web of Science ®Google Scholar
• Hanna R, Campbell R, Davies P. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature. 2008;456:409–412.
   PubMed Web of Science ®Google Scholar
• Campbell RL, Davies PL. Structure-function relationships in calpains. Biochem J. 2012;447:335–351.
   PubMed Web of Science ®Google Scholar
• Moldoveanu T, Gehring K, Green DR. Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature. 2008;456:404–408.
   PubMed Web of Science ®Google Scholar
• HH C, Lim D, SH L, et al. Homology modeling study of bovine μ-Calpain inhibitor-binding domains. Int J Mol Sci. 2014;15:7897–7938.
   PubMed Web of Science ®Google Scholar
• Liang Z, Demko V, Wilson R, et al. The catalytic domain CysPc of the DEK1 calpain is functionally conserved in land plants. Plant J. 2013;75:742–754.
   PubMed Web of Science ®Google Scholar
• Zimmerman P, Boring L, Jhang U-J. The calpain small subunit gene is essential: its inactivation results in embryonic lethality. IUBMB Life (International Union Biochem Mol Biol Life). 2000;50:63–68.
   Google Scholar
• Murachi T, Tanaka K, Hatanaka M, et al. Intracellular Ca2+-dependent protease (CALPAIN) and its high-molecular-weight endogenous inhibitor (CALPASTATIN). Adv Enzyme Regul. 1981;19:407–424.
   Google Scholar
• Laszlo K, Yunchao S. the critical role of calpain in cell proliferation. J Biomol Res Ther. 2014;03:112.
   Google Scholar
• Glading A, Lauffenburger DA, Wells A. Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol. 2002;12:46–54.
   PubMed Web of Science ®Google Scholar
• Mendoza P, Silva P, Díaz J, et al. Calpain2 mediates rab5-driven focal adhesion disassembly and cell migration. Cell Adh Migr. 2018;12:185–194.
   PubMed Web of Science ®Google Scholar
• Glading A, Chang P, Lauffenburger D, et al. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem. 2000;275:2390–2398.
   PubMed Web of Science ®Google Scholar
• Glading A, Überall F, Keyse SM, et al. Membrane proximal erk signaling is required for m-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem. 2001;276:23341–23348.
   PubMed Web of Science ®Google Scholar
• Carillo S, Pariat M, Steff AM, et al. Differential sensitivity of FOS and JUN family members to calpains. Oncogene. 1994;9:1679–1689.
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee SJ, Nguyen PM, et al. Regulation of cyclin D1 by calpain protease. J Biol Chem. 1997;272:28479–28484.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lu Q, Xie ZJ, et al. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene. 1997;14:255–263.
   PubMed Web of Science ®Google Scholar
• Carragher NO, Westhoff MA, Riley D, et al. v-src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol Cell Biol. 2002;22:257–269.
   PubMed Web of Science ®Google Scholar
• Santos DM, Xavier JM, Morgado AL, et al. Distinct regulatory functions of calpain 1 and 2 during neural stem cell self-renewal and differentiation. PLoS One. 2012;7:e33468.
   Web of Science ®Google Scholar
• Shu Y, Xiang M, Zhang P, et al. Wnt-5a promotes neural development and differentiation by regulating CDK5 via Ca 2+/Calpain pathway. Cell Physiol Biochem. 2019;51:2604–2615.
   Google Scholar
• Baudry M, Bi X. Calpain- 1 and Calpain-2: the yin and yang of synaptic plasticity and neurodegeneration. Trends Neurosci. 2016;39:235–245.
   PubMed Web of Science ®Google Scholar
• Baudry M. Calpain- 1 and calpain-2 in the brain: Dr. Jekill and Mr Hyde? Curr Neuropharmacol. 2019;17:823–829.
   PubMed Web of Science ®Google Scholar
• Su Y, Cui Z, Li Z, et al. Calpain-2 regulation of VEGF-mediated angiogenesis. Faseb J. 2006;20:1443–1451.
   PubMed Web of Science ®Google Scholar
• Zhang Y, NM L, Wang Y, et al. Endothelial cell calpain as a critical modulator of angiogenesis. Biochim Biophys Acta - Mol Basis Dis. 2017;1863:1326–1335.
   PubMed Web of Science ®Google Scholar
• Nassar D, Letavernier E, Baud L, et al. Calpain activity is essential in skin wound healing and contributes to scar formation. PLoS One. 2012;7:e37084.
   PubMed Web of Science ®Google Scholar
• Arthur JSC, Elce JS, Hegadorn C, et al. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol. 2000;20:4474–4481.
   PubMed Web of Science ®Google Scholar
• Bodnar RJ, Yates CC, Rodgers ME, et al. IP-10 induces dissociation of newly formed blood vessels. J Cell Sci. 2009;122:2064–2077.
   PubMed Web of Science ®Google Scholar
• Dutt P, Croall DE, Arthur JSC, et al. m-Calpain is required for preimplantation embryonic development in mice. BMC Dev Biol. 2006;6:3.
   PubMed Web of Science ®Google Scholar
• Takano J, Mihira N, Fujioka R, et al. Vital role of the calpain-calpastatin system for placental-integrity-dependent embryonic survival. Mol Cell Biol. 2011;31:4097–4106.
   PubMed Web of Science ®Google Scholar
• Azam M, Andrabi SS, Sahr KE, et al. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol. 2001;21:2213–2220.
   PubMed Web of Science ®Google Scholar
• Araujo H, Julio A, Cardoso M. Translating genetic, biochemical and structural information to the calpain view of development. Mech Dev. 2018;154:240–250.
   PubMed Web of Science ®Google Scholar
• Välimäki E, Cypryk W, Virkanen J, et al. calpain activity is essential for ATP-driven unconventional vesicle-mediated protein secretion and inflammasome activation in human macrophages. J Immunol. 2016;197:3315–3325.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rong H, Zhang FX, et al. A membrane potential- and calpain-dependent reversal of caspase-1 inhibition regulates canonical nlrp3 inflammasome. Cell Rep. 2018;24(2356–2369):e5.
   Google Scholar
• Davis MA, Fairgrieve MR, Den Hartigh A, et al. Calpain drives pyroptotic vimentin cleavage, intermediate filament loss, and cell rupture that mediates immunostimulation. Proc Natl Acad Sci U S A. 2019;116:5061–5070.
   PubMed Web of Science ®Google Scholar
• Mikosik A, Jasiulewicz A, Daca A, et al. Roles of calpain-calpastatin system (CCS) in human T cell activation. Oncotarget. 2016;7:76479–76495.
   PubMedGoogle Scholar
• Ono Y, Ojima K, Shinkai-Ouchi F, et al. An eccentric calpain, CAPN3/p94/calpain-3. Biochimie. 2016;122:169–187.
   PubMed Web of Science ®Google Scholar
• Ye Q, Campbell RL, Davies PL. Structures of human calpain-3 protease core with and without bound inhibitor reveal mechanisms of calpain activation. J Biol Chem. 2018;293:4056–4070.
   PubMed Web of Science ®Google Scholar
• Mahajan VB, Skeie JM, Bassuk AG, et al. Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. PLoS Genet. 2012;8:e1003001.
   Web of Science ®Google Scholar
• Wang Y, Li H, Zang S, et al. Photoreceptor cell–derived CAPN5 regulates retinal pigment epithelium cell proliferation through direct regulation of SLIT2 cleavage. Investig Ophthalmol Vis Sci. 2018;59:1810–1821.
   PubMed Web of Science ®Google Scholar
• Hata S, Abe M, Suzuki H, et al. Calpain 8/nCL-2 and Calpain 9/nCL-4 constitute an active protease complex, G-Calpain, involved in gastric mucosal defense. PLoS Genet. 2010;6:1–14.
   Web of Science ®Google Scholar
• Pánico P, Salazar AM, Burns AL, et al. Role of calpain-10 in the development of diabetes mellitus and its complications. Arch Med Res. 2014;45:103–115.
   PubMed Web of Science ®Google Scholar
• Ono Y, Saido TC, Sorimachi H. Calpain research for drug discovery: challenges and potential. Nat Rev Drug Discov. 2016;15:854–876.
   PubMed Web of Science ®Google Scholar
• Momeni HR. Role of calpain in apoptosis. Cell J. 2011;13:65–72.
   PubMed Web of Science ®Google Scholar
• Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res. 2012;96:32–37.
   PubMed Web of Science ®Google Scholar
• Mahaman YAR, Huang F, Kessete Afewerky H, et al. Involvement of calpain in the neuropathogenesis of Alzheimer’s disease. Med Res Rev. 2019;39:608–630.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Miyazaki A. Dysregulation of calpain proteolytic systems underlies degenerative vascular disorders. J Atheroscler Thromb. 2018;25:1–15.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhu X. The molecular mechanisms of calpains action on skeletal muscle atrophy. Physiol Res. 2016;65:547–560.
   PubMed Web of Science ®Google Scholar
• Lee MS, Kwon YT, Li M, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360–364.
   PubMed Web of Science ®Google Scholar
• Wen Y, Yu WH, Maloney B, et al. transcriptional regulation of β-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008;57:680–690.
   PubMed Web of Science ®Google Scholar
• Alberdi E, Sánchez-Gómez MV, Cavaliere F, et al. Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47:264–272.
   PubMed Web of Science ®Google Scholar
• Jin N, Yin X, Yu D, et al. Truncation and activation of GSK-3β by calpain I: A molecular mechanism links to tau hyperphosphorylation in Alzheimer’s disease. Sci Rep. 2015;5: Article number:8187.
   Web of Science ®Google Scholar
• Paudel HK, LewS J, AliS Z, et al. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with alzheimer’s paired helical filaments* Brain proline-directed protein kinase (BPDK), which contains a catalytic subunit homologous t. J Biol Chem. 1993;268:23512–23518.
   PubMed Web of Science ®Google Scholar
• Hanger DP, Hughes K, Woodgett JR, et al. Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 1992;147:58–62.
   PubMed Web of Science ®Google Scholar
• Subramanian V, Uchida HA, Ijaz T, et al. Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. J Cardiovasc Pharmacol. 2012;59:66–76.
   PubMed Web of Science ®Google Scholar
• Howatt DA, Balakrishnan A, Moorleghen JJ, et al. Leukocyte calpain deficiency reduces angiotensin II-induced inflammation and atherosclerosis but not abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2016;36:835–845.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Taketomi Y, Takimoto M, et al. m-calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation. 2011;124:2522–2532.
   PubMed Web of Science ®Google Scholar
• Su W, Kowalczyk AP, The V. E-cadherin cytoplasmic domain undergoes proteolytic processing during endocytosis. Mol Biol Cell. 2017;28:76–84.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Tonami K, Hata S, et al. Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing. J Clin Invest. 2016;126:3417–3432.
   PubMed Web of Science ®Google Scholar
• Cao T, Fan S, Zheng D, et al. Increased calpain-1 in mitochondria induces dilated heart failure in mice: role of mitochondrial superoxide anion. Basic Res Cardiol. 2019;114:17.
   Web of Science ®Google Scholar
• Wells GJ, Bihovsky R. Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: recent trends and developments. Exp Opin Ther Patents. 1998;8:1707–1727.
   Web of Science ®Google Scholar
• Liu S, Yin F, Zhang J, et al. The role of calpains in traumatic brain injury. Brain Inj. 2014;28:133–137.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bi X, Baudry M. Calpain- 2 as a therapeutic target for acute neuronal injury. Expert Opin Ther Targets. 2018;22:19–29.
   PubMed Web of Science ®Google Scholar
• Saatman KE, Bozyczko-Coyne D, Marcy V, et al. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol. 1996;55:850–860.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Larner SF, Liu MC, et al. Multiple alpha II-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. 2009;14:1289–1298.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Lopez D, et al. Protection against TBI-induced neuronal death with post-treatment with a selective calpain-2 inhibitor in mice. J Neurotrauma. 2018;35:105–117.
   PubMed Web of Science ®Google Scholar
• Storr SJ, Carragher NO, Frame MC, et al. The calpain system and cancer. Nat Rev Cancer. 2011;11:364–374.
   PubMed Web of Science ®Google Scholar
• Tan Y, Wu C, De Veyra T, et al. Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. J Biol Chem. 2006;281:17689–17698.
   PubMed Web of Science ®Google Scholar
• Conacci-Sorrell M, Ngouenet C, Anderson S, et al. Stress-induced cleavage of Myc promotes cancer cell survival. Genes Dev. 2014;28:689–707.
   PubMed Web of Science ®Google Scholar
• Gafni J, Cong X, Chen SF, et al. Calpain-1 cleaves and activates caspase-7. J Biol Chem. 2009;284:25441–25449.
   PubMed Web of Science ®Google Scholar
• Gil-Parrado S, Fernández-Montalván A, Assfalg-Machleidt I, et al. Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem. 2002;277::27217–27226.
   PubMed Web of Science ®Google Scholar
• Chen J, Wu Y, Zhang L, et al. Evidence for calpains in cancer metastasis. J Cell Physiol. 2019;234:8233–8240.
   PubMed Web of Science ®Google Scholar
• Cheng F, Mohanmed MM, Li Z, et al. Capn4 promotes colorectal cancer cell proliferation by increasing MAPK7 through activation of the Wnt/β-Catenin pathway. Exp Cell Res. 2018;363:235–242.
   PubMed Web of Science ®Google Scholar
• Wang E, Wang D, Li B, et al. Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/β-catenin pathway. Oncol Rep. 2017;37:379–387.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang G, Wang Y, et al. Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway. Oncol Lett. 2019;17:564–570.
   PubMed Web of Science ®Google Scholar
• Peng P, Wu W, Zhao J, et al. Decreased expression of Calpain-9 predicts unfavorable prognosis in patients with gastric cancer. Sci Rep. 2016;6:29604.
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhou A-X, Rouhi P, et al. Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response. Proc Natl Acad Sci. 2014;111:2560–2565.
   PubMed Web of Science ®Google Scholar
• Lasa-Elgarresta J, Mosqueira-Martín L, Naldaiz-Gastesi N, et al. Calcium mechanisms in limb-girdle muscular dystrophy with capn3 mutations. Int J Mol Sci. 2019;20:E4548.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Q, Youn JY, et al. Protein phosphotyrosine phosphatase 1B (PTP1B) in calpain dependent feedback regulation of vascular endothelial growth factor receptor (VEGFR2) in endothelial cells: implications in VEGF-dependent angiogenesis and diabetic wound healing. J Biol Chem. 2017;292:407–417.
   PubMed Web of Science ®Google Scholar
• Hatta T, Iemura SI, Ohishi T, et al. Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. Sci Rep. 2018;8:16756.
   Web of Science ®Google Scholar
• Zhang G, Fang T, Chang M, et al. Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling. Oncol Rep. 2018;40:1937–1946.
   PubMed Web of Science ®Google Scholar
• MacLeod JA, Gao Y, Hall C, et al. Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. Oncotarget. 2018;9:33382–33395.
   PubMedGoogle Scholar
• Pin F, Minero VG, Penna F, et al. Interference with Ca 2+ -dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front Physiol. 2017;8:213.
   PubMed Web of Science ®Google Scholar
• Maki M, Bagci H, Hamaguchi K, et al. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J Biol Chem. 1989;264:18866–18869.
   PubMed Web of Science ®Google Scholar
• Sher JH, Stracher A, Shafiq SA, et al. Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin. Proc Natl Acad Sci. 1981;78:7742–7744.
   PubMed Web of Science ®Google Scholar
• Mehdi S, Angelastro MR, Wiseman JS, et al. Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. Biochem Biophys Res Commun. 1988;157:1117–1123.
   PubMed Web of Science ®Google Scholar
• Donkor IO. Calpain inhibitors: A survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat. 2011;21:601–636.
   PubMed Web of Science ®Google Scholar
• Donkor IO. An updated patent review of calpain inhibitors (2012–2014). Expert Opin Ther Pat. 2015;25:17–31.
   PubMed Web of Science ®Google Scholar
• Tompa P, Buzder-Lantos P, Tantos A, et al. On the sequential determinants of calpain cleavage. J Biol Chem. 2004;279:20775–20785.
   PubMed Web of Science ®Google Scholar
• Cuerrier D, Moldoveanu T, Davies PL. Determination of peptide substrate specificity for μ-calpain by a peptide library-based approach: the importance of primed side interactions. J Biol Chem. 2005;280:40632–40641.
   PubMed Web of Science ®Google Scholar
• Farkas A, Tompa P, Friedrich P. Revisiting ubiquity and tissue specificity of human calpains. J Biol Chem. 2003;384:945–949.
   Google Scholar
• Emori Y, Kawasaki H, Imajoh S, et al. All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity expression of the cDNA fragments in escherichia coli. J Biol Chem. 1988;263:2364–2370.
   PubMed Web of Science ®Google Scholar
• Kiss R, Kovács D, Tompa P, et al. Local structural preferences of calpastatin, the intrinsically unstructured protein inhibitor of calpain. Biochemistry. 2008;47:6936–6945.
   PubMed Web of Science ®Google Scholar
• Hanna RA, Garcia-Diaz BE, Davies PL. Calpastatin simultaneously binds four calpains with different kinetic constants. FEBS Lett. 2007;581:2894–2898.
   PubMed Web of Science ®Google Scholar
• Alluri H, Grimsley M, Shaji CA, et al. Attenuation of blood-brain barrier breakdown and hyperpermeability by calpain inhibition. J Biol Chem. 2016;291:26958–26969.
   PubMed Web of Science ®Google Scholar
• Lin XY, Chen SZ. Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol Rep. 2017;37:1601–1610.
   PubMed Web of Science ®Google Scholar
• Wu HY, Tomizawa K, Matsushita M, et al. Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain. Neurosci Res. 2003;47:131–135.
   PubMed Web of Science ®Google Scholar
• Gil-Parrado S, Assfalg-Machleidt I, Fiorino F, et al. Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin. Biol Chem. 2003;384:395–402.
   PubMed Web of Science ®Google Scholar
• Fiorino F, Gil-Parrado S, Assfalg-Machleidt I, et al. A new cell-permeable calpain inhibitor. J Pept Sci. 2007;13:70–73.
   PubMed Web of Science ®Google Scholar
• Sengoku T, Bondada V, Hassane D, et al. Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity. Exp Neurol. 2004;188:161–170.
   PubMed Web of Science ®Google Scholar
• Popp O, Heidinger M, Ruiz-Heinrich L, et al. The calpastatin-derived calpain inhibitor CP1B reduces mRNA expression of matrix metalloproteinase-2 and −9 and invasion by leukemic THP-1 cells. Biol Chem. 2003;384:951–958.
   PubMed Web of Science ®Google Scholar
• Betts R, Weinsheimer S, Blouse GE, et al. Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. J Biol Chem. 2003;278:7800–7809.
   PubMed Web of Science ®Google Scholar
• Betts R, Anagli J. The β- and γ-CH2 of B27-WT’s Leu11 and ILE18 side chains play a direct role in calpain inhibition. Biochemistry. 2004;43:2596–2604.
   PubMed Web of Science ®Google Scholar
• Pfizer J, Assfalg-Machleidt I, MacHleidt W, et al. Inhibition of human μ-calpain by conformationally constrained calpastatin peptides. Biol Chem. 2008;389:83–90.
   PubMed Web of Science ®Google Scholar
• Anagli J, Han Y, Stewart L, et al. A novel calpastatin-based inhibitor improves postischemic neurological recovery. Biochem Biophys Res Commun. 2009;385:94–99.
   PubMed Web of Science ®Google Scholar
• Jo H, Meinhardt N, Wu Y, et al. Development of α-helical calpain probes by mimicking a natural protein-protein interaction. J Am Chem Soc. 2012;134:17704–17713.
   PubMed Web of Science ®Google Scholar
• Low KE, Ler S, Chen KJ, et al. rational design of calpain inhibitors based on calpastatin peptidomimetics. J Med Chem. 2016;59:5403–5415.
   PubMed Web of Science ®Google Scholar
• Zaretsky S, Scully CCG, Lough AJ, et al. Exocyclic control of turn induction in macrocyclic peptide scaffolds. Chem A Eur J. 2013;19:17668–17672.
   PubMed Web of Science ®Google Scholar
• Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012;1824:68–88.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Messina PA, Freed B, et al. Subsite requirements for peptide aldehyde inhibitors of human calpain I. Bioorg Med Chem Lett. 1997;7:539–544.
   Web of Science ®Google Scholar
• Kwang SL, Seon HS, Yong HL, et al. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors. Bioorg Med Chem Lett. 2005;15:2857–2860.
   PubMedGoogle Scholar
• Nam DH, Lee KS, Kim SH, et al. Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors. Bioorg Med Chem Lett. 2008;18:205–209.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jung SY, Jin C, et al. Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. Bioorg Med Chem Lett. 2009;19:502–507.
   PubMed Web of Science ®Google Scholar
• Jantos K, Kling A, Mack H, et al. Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. Bioorg Med Chem Lett. 2019;29:1968–1973.
   PubMedGoogle Scholar
• Lubisch W, Möller A. Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors. Bioorg Med Chem Lett. 2002;12:1335–1338.
   PubMed Web of Science ®Google Scholar
• Lubisch W, Beckenbach E, Bopp S, et al. Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem. 2003;46:2404–2412.
   PubMed Web of Science ®Google Scholar
• Nikkel AL, Martino B, Markosyan S, et al. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology. 2012;63:606–612.
   PubMed Web of Science ®Google Scholar
• Granic I, Nyakas C, Luiten PGM, et al. Calpain inhibition prevents amyloid-β-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology. 2010;59:334–342.
   PubMed Web of Science ®Google Scholar
• Kling A, Jantos K, Mack H, et al. Discovery of novel and highly selective inhibitors of calpain for the treatment of Alzheimer’s disease: 2-(3-phenyl-1H-pyrazol-1-yl)-nicotinamides. J Med Chem. 2017;60:7123–7138.
   PubMedGoogle Scholar
• Kling A, Jantos K, MacK H, et al. Mitigating the metabolic liability of carbonyl reduction: novel calpain inhibitors with p1′ extension. ACS Med Chem Lett. 2018;9:221–226.
   PubMed Web of Science ®Google Scholar
• Lon HK, Mendonca N, Goss S, et al. Pharmacokinetics, safety, tolerability, and pharmacodynamics of alicapistat, a selective inhibitor of human calpains 1 and 2 for the treatment of Alzheimer disease: an overview of phase 1 studies. Clin Pharmacol Drug Dev. 2019;8:290–303.
   PubMed Web of Science ®Google Scholar
• Lescop C, Herzner H, Siendt H, et al. Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy. Bioorg Med Chem Lett. 2005;15:5176–5181.
   PubMed Web of Science ®Google Scholar
• Weyermann P, Herzner H, Lescop C, et al. Synthesis and evaluation of calpain inhibitors carrying muscle cell targeting groups. Lett Drug Des Discov. 2006;3:152–158.
   Web of Science ®Google Scholar
• Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A. 1996;93:3428–3433.
   PubMed Web of Science ®Google Scholar
• Ovat A, Li ZZ, Hampton CY, et al. Peptidyl α-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem. 2010;53:6326–6336.
   PubMed Web of Science ®Google Scholar
• Li Z, Ortega-Vilain AC, Patil GS, et al. Novel peptidyl α-keto amide inhibitors of calpains and other cysteine proteases. J Med Chem. 1996;39:4089–4098.
   PubMed Web of Science ®Google Scholar
• Stracher A, Kesner L, Shulman A. Targeted delivery of pharmaceutical compounds. US8729024; 2007.
   Google Scholar
• Dugue R, Hassen GW, Shulman A, et al. Controlled cortical impact-induced neurodegeneration decreases after administration of the novel calpain-inhibitor Gabadur. Brain Res Bull. 2018;142:368–373.
   PubMed Web of Science ®Google Scholar
• Hassen GW, Kesner L, Stracher A, et al. Effects of novel calpain inhibitors in transgenic animal model of parkinson’s disease/dementia with Lewy bodies. Sci Rep. 2018;8:18083.
   PubMed Web of Science ®Google Scholar
• Rasbach KA, Arrington DD, Odejinmi S, et al. Identification and optimization of a novel inhibitor of mitochondrial calpain 10. J Med Chem. 2008;52:181–188.
   Web of Science ®Google Scholar
• Smith MA, McInnes C, Whitaker RM, et al. Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol. 2012;7:1410–1419.
   PubMed Web of Science ®Google Scholar
• Jones MA, Morton JD, Coxon JM, et al. Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem. 2008;16:6911–6923.
   PubMed Web of Science ®Google Scholar
• Jones S, Jones M, McNabb S, et al. N-Heterocyclic Dipeptide Aldehyde Calpain Inhibitors. Protein Pept Lett. 2009;16:1466–1472.
   PubMed Web of Science ®Google Scholar
• Madala PK, Tyndall JDA, Nall T, et al. Update 1 of: proteases universally recognize beta strands in their active sites. Chem Rev. 2010;110:PR1–PR31.
   PubMed Web of Science ®Google Scholar
• Cherney RJ, Wang L, Meyer DT, et al. Macrocyclic amino carboxylates as selective MMP-8 inhibitors. J Med Chem. 1998;41:1749–1751.
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186–189.
   PubMed Web of Science ®Google Scholar
• Abell AD, Jones MA, Coxon JM, et al. Molecular modeling, synthesis, and biological evaluation of macrocyclic calpain inhibitors. Angew Chemie Int Ed. 2009;48:1455–1458.
   PubMed Web of Science ®Google Scholar
• Chen H, Jiao W, Jones MA, et al. New tripeptide-based macrocyclic calpain inhibitors formed by n-alkylation of histidine. Chem Biodivers. 2012;9:2473–2484.
   PubMed Web of Science ®Google Scholar
• Jones SA, Neilsen PM, Siew L, et al. A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease. ChemMedChem. 2013;8:1918–1921.
   PubMed Web of Science ®Google Scholar
• Powers JC, Boone R, Carroll DL, et al. Reaction of azapeptides with human leukocyte elastase and porcine pancreatic elastase new inhibitors and active site titrants. J Biol Chem. 1984;259:4288–4294.
   PubMed Web of Science ®Google Scholar
• Magrath J, Abeles RH. Cysteine protease inhibition by azapeptide esters. J Med Chem. 1992;35:4279–4283.
   PubMed Web of Science ®Google Scholar
• Bánóczi Z, Tantos Á, Farkas A, et al. New m-calpain substrate-based azapeptide inhibitors. J Pept Sci. 2013;19:370–376.
   PubMed Web of Science ®Google Scholar
• Hanada K, Tamai M, Yamagishi M, et al. Isolation and characterization of e–64, a new thiol protease inhibitor. Agric Biol Chem. 1978;42:523–528.
   Web of Science ®Google Scholar
• Dókus LE, Menyhárd DK, Tantos Á, et al. Probing of primed and unprimed sites of calpains: design, synthesis and evaluation of epoxysuccinyl-peptide derivatives as selective inhibitors. Eur J Med Chem. 2014;82:274–280.
   PubMed Web of Science ®Google Scholar
• Schiefer IT, Tapadar S, Litosh V, et al. Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors. J Med Chem. 2013;56:6054–6068.
   PubMed Web of Science ®Google Scholar
• Stuart BG, Coxon JM, Morton JD, et al. Molecular modeling: A search for a calpain inhibitor as a new treatment for cataractogenesis. J Med Chem. 2011;54:7503–7522.
   PubMed Web of Science ®Google Scholar
• Muralidharan AR, Selvaraj C, Singh SK, et al. Structure-based virtual screening and biological evaluation of a calpain inhibitor for prevention of selenite-induced cataractogenesis in an in vitro system. J Chem Inf Model. 2015;55:1686–1697.
   PubMed Web of Science ®Google Scholar
• Muralidharan AR, Selvaraj C, Singh SK, et al. Virtual screening based on pharmacophoric features of known calpain inhibitors to identify potent inhibitors of calpain. Med Chem Res. 2014;23:2445–2455.
   Web of Science ®Google Scholar
• Kalash L, Cresser-Brown J, Habchi J, et al. Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space. Eur J Med Chem. 2018;157:1264–1275.
   PubMed Web of Science ®Google Scholar
• Wang KKW, Nath R, Posner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell- permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A. 1996;93:6687–6692.
   PubMed Web of Science ®Google Scholar
• Da LG, Chattopadhyay D, Maki M, et al. Crystal structure of calcium bound domain VI of calpain at 1.9 Å resolution and its role in enzyme assembly, regulation, and inhibitor binding. Nat Struct Biol. 1997;4:539–547.
   PubMedGoogle Scholar
• Adams SE, Parr C, Miller DJ, et al. Potent inhibition of Ca2+-dependent activation of calpain-1 by novel mercaptoacrylates. Medchemcomm. 2012;3:566–570.
   Web of Science ®Google Scholar
• Adams SE, Rizkallah PJ, Miller DJ, et al. The structural basis of differential inhibition of human calpain by indole and phenyl α-mercaptoacrylic acids. J Struct Biol. 2014;187:236–241.
   PubMed Web of Science ®Google Scholar
• Adams SE, Robinson EJ, Miller DJ, et al. Conformationally restricted calpain inhibitors. Chem Sci. 2015;6:6865–6871.
   PubMed Web of Science ®Google Scholar
• Low KE, Karunan Partha S, Davies PL, et al. Allosteric inhibitors of calpains: reevaluating inhibition by PD150606 and LSEAL. Biochim Biophys Acta Gen Subj. 2014;1840:3367–3373.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719–2740.
   PubMed Web of Science ®Google Scholar
• Tong-Jun L. Inhibition of calpain reduces allergic inflammation. US20090297510A1; 2009.
   Google Scholar
• Melloni E, Michetti M, Salamino F, et al. Molecular and functional properties of a calpain activator protein specific for mu-isoforms. J Biol Chem. 1998;273:12827–12831.
   PubMed Web of Science ®Google Scholar
• Michetti M, Viotti PL, Melloni E, et al. Mechanism of action of the calpain activator protein in rat skeletal muscle. Eur J Biochem. 1991;202:1177–1180.
   PubMedGoogle Scholar
• Tompa P, Mucsi Z, Orosz G, et al. Calpastatin subdomains A and C are activators of calpain. J Biol Chem. 2002;277:9022–9026.
   PubMed Web of Science ®Google Scholar
• Bánoczi Z, Tantos Á, Farkas A, et al. Synthesis of cell-penetrating conjugates of calpain activator peptides. Bioconjug Chem. 2007;18:130–137.
   PubMed Web of Science ®Google Scholar
• Világi I, Kiss DS, Farkas A, et al. Synthetic calpain activator boosts neuronal excitability without extra Ca2+. Mol Cell Neurosci. 2008;38:629–636.
   PubMed Web of Science ®Google Scholar
• Hiwasa T. Induction of apoptosis by a calpain stimulator, ONO-3403. Apoptosis. 1996;1:75.
   Google Scholar
• Zhang W, Liu J, Sun R, et al. Calpain activator dibucaine induces platelet apoptosis. Int J Mol Sci. 2011;12:2125–2137.
   PubMed Web of Science ®Google Scholar
• Takeda S, Watanabe K, Aramaki H. Phytocannabinoids, ∆9-tetrahydrocannabinol and cannabidiol, as human calpain-1 (CAPN1) activators. Fundam Toxicol Sci. 2017;4:101–103.
   Google Scholar
• Bartoli M, Roudaut C, Martin S, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy Type 2A. Mol Ther. 2006;13:250–259.
   PubMed Web of Science ®Google Scholar
• Roudaut C, Le Roy F, Suel L, et al. Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation. 2013;128:1094–1104.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Ishiguro SI, Hirano S, et al. Inhibitory peptide of mitochondrial μ-calpain protects against photoreceptor degeneration in rhodopsin transgenic s334ter and p23h rats. PLoS One. 2013;8:e71650.
   Web of Science ®Google Scholar
• Parkes C, Kembhavi AA, Barrett AJ. Calpain inhibition by peptide epoxides. Biochem J. 1985;230:509–516.
   PubMed Web of Science ®Google Scholar
• Salamino F, De Tullio R, Michetti M, et al. Modulation of calpastatin specificity in rat tissues by reversible phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 1994;199:1326–1332.
   PubMed Web of Science ®Google Scholar